

**UCC Library and UCC researchers have made this item openly available.
Please [let us know](#) how this has helped you. Thanks!**

Title	Benzodiazepine use among young attendees of an Irish substance treatment center
Author(s)	Murphy, Kevin D.; Byrne, Stephen; McCarthy, Suzanne; Lambert, Sharon; Sahn, Laura J.
Publication date	2014-05
Original citation	Murphy, K. D., Byrne, S., McCarthy, S., Lambert, S. and Sahn, L. J. (2014) 'Benzodiazepine Use Among Young Attendees of an Irish Substance Treatment Center', Journal of Addiction Medicine, 8(3), pp. 199-204. doi: 10.1097/ADM.0000000000000025
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://journals.lww.com/journaladdictionmedicine/Fulltext/2014/05000/Benzodiazepine_Use_Among_Young_Attendees_of_an.8.aspx http://dx.doi.org/10.1097/ADM.0000000000000025 Access to the full text of the published version may require a subscription.
Rights	© 2014 American Society of Addiction Medicine. This is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Addiction Medicine, doi: 10.1097/ADM.0000000000000025
Item downloaded from	http://hdl.handle.net/10468/6178

Downloaded on 2021-05-14T01:17:41Z

Journal of Addiction Medicine

Benzodiazepine use amongst young attendees of an Irish substance treatment centre --Manuscript Draft--

Manuscript Number:	JAM-D-13-00108R1
Full Title:	Benzodiazepine use amongst young attendees of an Irish substance treatment centre
Short Title:	Benzodiazepine use amongst young attendees of an Irish substance treatment centre
Article Type:	Original Research
Keywords:	Benzodiazepines, Ireland, young people, treatment centre
Corresponding Author:	Kevin Daniel Murphy, BPharm University College Cork Cork, IRELAND
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University College Cork
Corresponding Author's Secondary Institution:	
First Author:	Kevin Daniel Murphy, BPharm
First Author Secondary Information:	
Order of Authors:	Kevin Daniel Murphy, BPharm Suzanne McCarthy, PhD Stephen Byrne, PhD Sharon Lambert, PhD Laura Jane Sahm, PhD
Order of Authors Secondary Information:	
Manuscript Region of Origin:	IRELAND
Abstract:	<p>Objective</p> <p>To describe the demographic characteristics of those service-users attending Matt Talbot Services, and their current and past substance use, and to explore the use of benzodiazepines amongst this group.</p> <p>Method</p> <p>There were 198 service-users who attended a substance misuse treatment centre in Cork, Ireland between January 2005 and August 2011.</p> <p>Results</p> <p>Benzodiazepines had ever been used by 51.0%, and of these, 55.8% were regular benzodiazepine users. The mean age of first use was 14.9 ± 1.40 years. Regular users of benzodiazepines were regular users of significantly more substances (3, IQR=2-3) when compared with non-regular benzodiazepine users (1, IQR=1-2). Regular benzodiazepine users showed more behavioural signs (12, IQR=10-14) than non-regular users (9, IQR=7-12). Physical signs were significantly different between regular (8, IQR=6-11) and non-regular (5, IQR=3-10) users.</p> <p>Conclusions</p> <p>The effects of benzodiazepine misuse affect the individual, their family, and society as whole through hospitalisation, substance treatment and crime. Identifying regular benzodiazepine users can help reduce the burden of benzodiazepines.</p>

Abstract

Objective

To describe the demographic characteristics of those service-users attending Matt Talbot Services, and their current and past substance use, and to explore the use of benzodiazepines amongst this group.

Method

There were 198 service-users who attended a substance misuse treatment centre in Cork, Ireland between January 2005 and August 2011.

Results

Benzodiazepines had ever been used by 51.0%, and of these, 55.8% were regular benzodiazepine users. The mean age of first use was 14.9 ± 1.40 years. Regular users of benzodiazepines were regular users of significantly more substances (3, IQR=2-3) when compared with non-regular benzodiazepine users (1, IQR=1-2). Regular benzodiazepine users showed more behavioural signs (12, IQR=10-14) than non-regular users (9, IQR=7-12). Physical signs were significantly different between regular (8, IQR=6-11) and non-regular (5, IQR=3-10) users.

Conclusions

The effects of benzodiazepine misuse affect the individual, their family, and society as whole through hospitalisation, substance treatment and crime. Identifying regular benzodiazepine users can help reduce the burden of benzodiazepines.

1. Introduction

1.1. Background

Treatment for substance misuse is a global issue. In 2010, there were between 3.1 and 7.2 million people who received treatment for substance dependence (UNODC, 2012). This is similar to the estimate of treatment uptake in 2005, which was around 3.7 million people (UNODC, 2007). It can be seen that there was little change in these numbers between these two periods. In Europe however, a different trend is observed as there has been a consistent rise in the number of people accessing drug treatment. In 2005 there were approximately 326,000 people attending drug treatment centres, but by 2010 this had increased by 45% (EMCDDA, 2007b, 2012a). This increase has also been mirrored in first-time users of the treatment centres which showed that the numbers increased 38% to approximately 177,700 (EMCDDA, 2007a, 2012a). Ireland has not been left untouched by this trend, with an approximate 35% increase in the number of cases handled by treatment centres in Ireland between 2005 and 2010 (Bellerose, Carew, & Lyons, 2011). In the same period of time, there was a 59% increase in the number of new persons entering into treatment. In 2010, 9.3% of cases (equivalent to 707 people) related to those aged less than 18 years of age, which was a 75% increase in the number of adolescents in treatment in 2005.

Whilst international treatment service utilisation figures are not available nonetheless in Europe, there was a 94% increase in the number of under-25s accessing treatment between 2005 and 2010 (EMCDDA, 2012b). Lifetime drug use amongst 15-34 years olds in Ireland has increased between 2002 and 2011 by approximately 10% from 25.9% to 35.7% (National Advisory Committee on Drugs, 2011). The most commonly used drugs in the year previous in this age group in 2010/2011 were alcohol (86.3%), tobacco (37.3%), opiates other than heroin [such as codeine, oxycodone and morphine] (28.3%), cannabis (10.3%), synthetic psychoactive substances (6.7%), and

1 sedatives/tranquilisers (4.8%). The sedative/tranquiliser category of drugs was the only category in
2 which a rise was observed since the previous survey done in 2006/2007. In a recent review of
3
4 substance use amongst young people, benzodiazepines were the only substance reviewed whose
5
6 prevalence did not decrease over its 10-year review period (Murphy, Sahn, McCarthy *et al.*, 2013).
7
8 These two studies highlight that benzodiazepine misuse is not following the trend of decreasing use
9
10 as other substances are.
11

12
13
14 Progress has been made in reducing of the numbers of young people using benzodiazepines in
15
16 Europe. Between 1995 and 2011, the percentage of 15/16 year olds that had used benzodiazepines
17
18 without a prescription decreased from 7% (Bjorn Hibell, Andersson, Bjarnason *et al.*, 1997) to 3%
19
20 (Björn Hibell, Guttormsson, Ahlström *et al.*, 2012), although this is greater than 2003 levels, 2%
21
22 (Bjorn Hibell, Andersson, Bjarnason *et al.*, 2004). This is in contrast to the percentage of young
23
24 people who are prescribed benzodiazepines in Ireland which has decreased from 11% in 1999 (Bjorn
25
26 Hibell, Andersson, Salme *et al.*, 2000) to 9% in 2011 (Björn Hibell, Guttormsson, Ahlström, *et al.*,
27
28 2012). Combining these, it can be estimated that approximately 1-in-10 Irish 15/16 year olds use
29
30 benzodiazepines. Another method of measuring benzodiazepine usage amongst young people in
31
32 Ireland is to look at the number of young people entering treatment services in Ireland. Between
33
34 2003 and 2008, there was a minimum of a 5-fold increase in the number of young people aged less
35
36 than 18 years who received treatment for benzodiazepine use (Bellerose, Lyons, Carew *et al.*, 2010).
37
38
39
40
41
42

43
44 Benzodiazepines at therapeutic levels can have serious short-term side-effects, and chronic use can
45
46 result in long-term consequences. Acute use of benzodiazepines can impair the perception of risk,
47
48 which can lead to hazardous activities such as high-risk sexual behaviour and reckless driving
49
50 (Dassanayake, Michie, Carter *et al.*, 2011; Griffin, Kaye, Bueno *et al.*, 2013). Benzodiazepines can also
51
52 lead to paradoxical reactions such as restlessness, agitation, anxiety, aggressive behaviour, and
53
54 delusions (Irish Medicines Board, 2011; Parsa, 2011). There is evidence that these paradoxical
55
56 reactions are more likely to occur to those at either extremes of age i.e. a younger or older age
57
58
59
60
61

1 (Mancuso, Tanzi, & Gabay, 2004), and that combining with alcohol can increase the occurrence of
2 violent behaviour (Forsyth, Khan, & McKinlay, 2011). Cognitive impairment is a well-documented
3
4 side-effect of benzodiazepine use (M. J. Barker, K. M. Greenwood, M. Jackson *et al.*, 2004; Boeuf-
5
6 Cazou, Bongue, Ansiau *et al.*, 2011; Billioti de Gage, Begaud, Bazin *et al.*, 2012), both short-term and
7
8 long-term. There is evidence that these effects can remain even after treatment with
9
10 benzodiazepines has ceased (Melinda J. Barker, Kenneth M. Greenwood, Martin Jackson *et al.*, 2004;
11
12 Stewart, 2005), although this is not without dispute (Verdoux, Lagnaoui, & Begaud, 2005). Although
13
14 not directly related to benzodiazepines, it is also interesting to note in a National Office of Suicide
15
16 Prevention report that benzodiazepines were the second leading method of self-harming in Ireland,
17
18 after alcohol, in 2011, resulting in 3611 hospitalisations (National Suicide Research Foundation,
19
20 2012). The significance of benzodiazepines in self-harm is such that the report views restricting
21
22 access to benzodiazepines as a priority.
23
24
25
26
27
28

29 **1.2. Aims**

30
31
32 The aim of this paper is to characterise service-users who attend Matt Talbot Services (MTS) in the
33
34 south of Ireland.
35
36
37

38 **Objective:**

39
40
41 To describe the demographic characteristics of those service-users attending MTS, and their current
42
43 and past substance use, and to explore the use of benzodiazepines amongst this group.
44
45
46

47 **2. Methods**

48 49 50 51 **2.1. Design**

52
53
54 Ethical Approval for this research was gained from the Clinical Research Ethics Committee of the
55
56 Cork Teaching Hospitals. The study used data collected from service-users who entered treatment
57
58 with MTS between 2005 and August 2011. Applicants were initially interviewed by MTS staff to
59
60
61

1 identify those who would benefit from treatment. Those who passed the initial screening were
2 accepted for treatment, while those not accepted were referred to alternatively-tiered services that
3 could provide more appropriate treatment. A description of the 4-tier structure of mental health
4 services is available elsewhere (Corrigan & O' Gorman, 2007). A total of 198 patient files were used
5 in the study. Assessment was aided by the use of assessment forms. One of the forms included a
6 section on the physical and behavioural impact of substance use. This was made up of 16 common
7 behavioural symptoms and 12 physical signs of substance misuse. Service-users were asked to
8 indicate if they had experienced any of these because of their substance misuse.
9

20 **2.2. Analyses**

23 Descriptive analysis of demographic data was done to provide a background of the service-user
24 population type. Further descriptive analysis was performed on data relating to recent substance
25 use, and examined by age and year of access to treatment. Regular benzodiazepine use was defined
26 as benzodiazepine use in the previous month. This is a common measure of current use in the
27 substance misuse field (National Advisory Committee on Drugs, 2011; European Monitoring Centre
28 for Drugs and Drug Addiction, 2006). For the comparison of regular benzodiazepine users and non-
29 regular benzodiazepine users, an independent t-test was performed on normally-distributed data,
30 while the Mann-Whitney U test was performed on non-normally-distributed continuous/interval
31 data. For nominal data, Pearson's chi-square analysis was performed (with Yate's continuity
32 correction for 2x2 tables), and where expected values fell below 1 (or 5 for 2x2 tables), Fisher's Exact
33 Test was used instead. A significance level of $\alpha=0.05$ was used for any inferential statistics
34 calculated. All statistical analyses were performed using Predictive Analytics SoftWare Statistics
35 (PASW; SPSS Inc. Chicago, Ill.) version 18.0.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

55 **3. Results**

59 **3.1 Demographic data**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

There were 198 service-users included in this study. Because of the number of incomplete forms, the sample numbers will vary between statistics; sample numbers are provided for each statistic reported.

97.9% (n=185) of service-users were male. The age of service-users that had details (n=163) ranged from 13-21 and their mean age was 16.4 years with a standard deviation (SD) of 1.25 years. Referral to the service has increased from two in 2005 up to 49 in 2010, with 29 service-users accessing treatment up to August 2011, as can be seen in Figure 1.

A breakdown of referral sources can be seen in Table 1. Juvenile Liaison officers (JLOs) were responsible for the most referrals (24.5%), while family members were the second largest group of referrals at 18.6%. Combining the referrals from JLOs and Probation officers, it can be seen that the Department of Justice is responsible for nearly half of all referrals (48.7%), whereas referrals from Department of Social Protection workers (social workers and youth centres) accounted for only 20.3% of total referrals.

Of the service-users who answered (n=184), 98.9% had ever consumed an alcoholic drink (See Table 2). The median age of first consumption was 13 years (IQR=12-14.75). Cannabis and tobacco followed closely with lifetime use at 93.9% and 92.7% respectively. Cocaine and benzodiazepines were the only remaining substances that had lifetime use levels over 50% (54.3% and 51.0% respectively).

3.2 Benzodiazepine use

Benzodiazepines had ever been used by 80/157 of the service-users. Of these, 43 (55.8%) service-users used benzodiazepines in the previous month, a measure of regular use (3 service-users did not answer the question). Daily use was recorded by 9 service-users, 19 service-users used benzodiazepines 2-6 times a week, and use of once a week or less was recorded for 15 service-users. The average age of first benzodiazepine use was 14.9 ± 1.40 years.

1 Characteristics of service-users entering treatment and their substance use history, as it relates to
2 benzodiazepines, are examined in Table 3.
3

4
5 A comparative examination of regular and non-regular users showed no significant difference in the
6 age of first benzodiazepine use, as can be seen in Table 4. Regular users of benzodiazepines were
7
8 regular users of significantly more substances (3, IQR=2-3) when compared with non-regular
9
10 benzodiazepine users (1, IQR=1-2).
11
12

13
14
15 Regular benzodiazepine users showed more behavioural signs (12, IQR=10-14) than non-regular
16
17 users (9, IQR=7-12). Similarly, the physical signs were significantly different between regular (8,
18
19 IQR=6-11) and non-regular (5, IQR=3-10) users. Both behavioural and physical signs were examined
20
21 for differences between regular and non-regular users. Reporting of paranoia ($p=0.018$), loss of
22
23 interest in sports and hobbies ($p=0.039$) and attention-seeking behaviour ($p=0.022$) were behaviours
24
25 that differed significantly for regular and non-regular users. Pale/white skin ($p=0.031$) and vomiting
26
27 ($p=0.031$) were the physical signs that were significantly different in both groups (See **Error!**
28
29
30
31
32 **Reference source not found.**)
33
34
35
36
37
38

39 **4. Discussion**

40 41 42 **4.1. Summary**

43
44
45 This study examined the substance use history of a cohort of service-users attending an outpatient
46
47 substance misuse treatment centre. An examination of these service-users' background was also
48
49 conducted. The majority of those attending the service were male and the mean age was 16.4 years.
50
51
52 The biggest source of referrals from this cohort was from Juvenile Liaison Officers, which accounted
53
54 for approximately a third of all referrals. Alcohol, cannabis, and tobacco were all experimented by
55
56 over 90% of attendees.
57
58
59
60
61
62

1 Benzodiazepines had been experimented on by over half of the attendees, while over a quarter of
2 attendees use benzodiazepines more than once a month, and the mean age of first benzodiazepine
3 use was 14.9 years. A comparison of regular benzodiazepine users and non-regular benzodiazepine
4 users showed that regular users experienced more behavioural symptoms. Paranoia, attention-
5 seeking behaviour, and loss of interest in sports were shown to occur more in regular
6 benzodiazepine users. Regular users also reported more physical symptoms, with pallor and
7 vomiting being significantly more common in regular users.
8

9
10
11
12
13
14
15
16
17 There is a large discrepancy between the number of males and females that attended the treatment
18 centre. The majority of service-users in treatment centres are generally male, and this can be seen in
19 many other studies (Che, Assanangkornchai, McNeil *et al.*, 2011). The overwhelming majority of
20 attendees were male in this study (97.9%), and this is partially due to the aforementioned bias.
21 However another cause must be factored in which is the mission statement of MTS was to help
22 males that had substance dependence issues. Unofficially, they would accept females in crisis
23 situations, so this kept the number of female clients lower than would be expected. This policy was
24 changed in 2010 to accept both males and females. Regular admission of females should bring the
25 gender ratio back in line with the studies shown above.
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Delusions such as paranoia can be known to occur with benzodiazepine use and this effect is classed
40 in a category known as paradoxical reactions (Irish Medicines Board, 2011). The Summary of Product
41 Characteristics (SPC) for Valium states that delusions occur in response to using benzodiazepines
42 predominantly in the elderly and in children (Irish Medicines Board, 2011). Attention-seeking
43 behaviour is often a symptom of borderline personality disorder (Aviram, Brodsky, & Stanley, 2006)
44 and histrionic disorder (Bakkevig & Karterud, 2010). Both of these disorders have been associated
45 with benzodiazepine dependence, possibly because they are prone to depression and anxiety
46 (Konopka, Pełka-Wysiecka, Grzywacz *et al.*, 2013). The loss of interest in sport may be related to
47 effects of benzodiazepines. It is a common effect of regular substance use; it is listed as one of the
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 criteria for substance dependence in the Tenth Revision of the International Statistical Classification
2 of Diseases and Related Health Problems (World Health Organisation, 1992). Specifically for
3 benzodiazepines, if they are taken at clinical doses can lead to fatigue, drowsiness, decreased
4 alertness, and depression (Irish Medicines Board, 2011). All of these side effects can lead to a
5 decreased motivation which can result in decreased time spent on sports and hobbies.
6
7
8
9

10
11
12 Skin pallor in benzodiazepine use is related to benzodiazepine withdrawal and can last weeks after
13 withdrawal (Lader, 2011). There does not appear to be a link benzodiazepine use and vomiting
14 according to SPCs. There was a weak link in the literature that described benzodiazepines as a
15 potential anti-emetic (Yeo, Jung, Ryu *et al.*, 2009). This suggests that vomiting may be a
16 benzodiazepine withdrawal symptom, and there are cases reports that would support this
17 hypothesis (Lin, Ma, & Liu, 2013), as well as evidence from primate research (Sannerud, Alien, Cook
18 *et al.*, 1991), and reviews (Dickinson, Rush, & Radcliffe, 1990).
19
20
21
22
23
24
25
26
27
28
29

30 Looking more generally at negative behavioural and physical symptoms, regular benzodiazepine
31 users experienced more behavioural and physical effects than non-regular users. This is to be
32 expected as regular users will have more problems than others, however it is surprising that regular
33 users experienced a wider spectrum of symptoms. In the case of physical symptoms, the difference
34 is greater than 50%. It would be difficult to explain this discrepancy alone by increased
35 benzodiazepine use; that would more likely lead to increased occurrence of similar symptoms. One
36 possible factor that could influence this result was the difference between the numbers of regular
37 medicines used by both groups of benzodiazepine users. Polysubstance use could account for a
38 portion of the extra symptoms experienced by regular benzodiazepine users.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **4.2. Limitations**

57
58
59
60
61
62
63
64
65

1 This study was cross-sectional in design. The ability to generalise these data to other substance
2 misuse centres should be done cautiously. This is a retrospective study so the researchers had no
3
4 control over the design of the forms used by the staff at the MTS. This would have been
5
6 advantageous as it would have been possible to customise the form so that a more thorough data
7
8 could have been derived from it. Including further information on psychosocial and physical
9
10 symptoms could provide a clearer picture of the experiences of these service-users. More
11
12 information about the service-users' family history and their interests may help give researchers a
13
14 better perspective on how their substance misuse fits in their lives.
15
16
17
18

19 This study surveyed adolescent service-users attending a substance misuse treatment centre. This is
20
21 a specialised population that is not comparable to the general population. The level of drug use will
22
23 be substantially higher among this population than among the population of adolescents in Ireland.
24
25 Another factor that limits its generalisability to the general population is that the population is
26
27 predominantly male. It has been mentioned previously that this is the case in other treatment
28
29 centres internationally and may allow for comparison with other treatment centres.
30
31
32
33

34 **5. Conclusions**

35
36
37 This study presents data on the use of benzodiazepines among Irish adolescents attending a drug
38
39 treatment centre. It is important that awareness about the level and severity of adolescent use of
40
41 benzodiazepines is disseminated throughout the community, in particular among healthcare
42
43 professionals. Benzodiazepines are powerful prescription medications used for a wide range of
44
45 indications, including anxiety, insomnia, and epilepsy. Half of those who had taken benzodiazepines
46
47 in this study became regular users. Recreational use of benzodiazepines can have acute and chronic
48
49 effects, especially in a formative stage of life such as adolescence. Paranoia, attention-seeking
50
51 behaviour, loss of interest in sports, pallor, and vomiting could indicate regular benzodiazepine use.
52
53 Regular benzodiazepine users often are polysubstance users and the risks of mixing substances
54
55 should be known. The effects of benzodiazepine misuse affect the individual, their family, and
56
57
58
59
60
61
62
63
64
65

1 society as whole through hospitalisation, substance treatment and crime. Identifying regular
2 benzodiazepine users can help reduce the burden of benzodiazepines.
3
4
5
6
7

8 **6. References**

- 9
10
11
12 Aviram, R. B., Brodsky, B. S., & Stanley, B. (2006). Borderline personality disorder, stigma, and
13 treatment implications. *Harv Rev Psychiatry*, 14(5), 249-256. doi:
14 10.1080/10673220600975121
15
16
17
18
19 Bakkevig, J. F., & Karterud, S. (2010). Is the Diagnostic and Statistical Manual of Mental Disorders,
20 Fourth Edition, histrionic personality disorder category a valid construct? *Comprehensive*
21 *Psychiatry*, 51(5), 462-470. doi: <http://dx.doi.org/10.1016/j.comppsy.2009.11.009>
22
23
24
25
26
27 Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004). Cognitive effects of long-term
28 benzodiazepine use: a meta-analysis. *CNS Drugs*, 18(1), 37-48.
29
30
31 Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004). Persistence of cognitive effects
32 after withdrawal from long-term benzodiazepine use: a meta-analysis. *Archives of Clinical*
33 *Neuropsychology*, 19(3), 437-454. doi: [http://dx.doi.org/10.1016/S0887-6177\(03\)00096-9](http://dx.doi.org/10.1016/S0887-6177(03)00096-9)
34
35
36
37
38
39 Bellerose, D., Carew, A.-M., & Lyons, S. (2011). Trends in treated problem drug use in Ireland 2005 to
40 2010 *HRB Trends Series 12*. Dublin: Health Research Board.
41
42
43 Bellerose, D., Lyons, S., Carew, A.-M., Walsh, S., & Long, J. (2010). Problem benzodiazepine use in
44 Ireland: treatment (2003 to 2008) and deaths (1998 to 2007) *HRB Trends Series 9*. Dublin:
45 Health Research Board.
46
47
48
49
50 Billioti de Gage, S., Begaud, B., Bazin, F., *et al.* (2012). Benzodiazepine use and risk of dementia:
51 prospective population based study. *BMJ*, 345, e6231.
52
53
54
55 Boeuf-Cazou, O., Bongue, B., Ansiau, D., Marquie, J. C., & Lapeyre-Mestre, M. (2011). Impact of long-
56 term benzodiazepine use on cognitive functioning in young adults: the VISAT cohort. *Eur J*
57 *Clin Pharmacol*, 67(10), 1045-1052. doi: 10.1007/s00228-011-1047-y
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Che, Y., Assanangkornchai, S., McNeil, E., Li, J., You, J., & Chongsuvivatwong, V. (2011). Patterns of attendance in methadone maintenance treatment program in Yunnan Province, China. *The American Journal of Drug and Alcohol Abuse*, 37(3), 148-154. doi:doi:10.3109/00952990.2010.535578
- Corrigan, D., & O' Gorman, A. (2007). Report of the HSE Working Group on Residential Treatment & Rehabilitation (Substance Users). Dublin: HSE Working Group on Residential Treatment & Rehabilitation.
- Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011). Effects of benzodiazepines, antidepressants and opioids on driving. *Drug Safety*, 34(2), 125-156.
- Dickinson, B., Rush, P., & Radcliffe, A. (1990). Alprazolam use and dependence. A retrospective analysis of 30 cases of withdrawal. *Western Journal of Medicine*, 152(5), 604.
- EMCDDA. (2007a). Table TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005. Part (i) Total numbers of new clients entering treatment. Retrieved 26/11/2012, from European Monitoring Centre for Drugs and Drug Addiction <http://www.emcdda.europa.eu/stats07/tditab02a>
- EMCDDA. (2007b). Table TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005. Part (ii) Total numbers of all clients entering treatment. Retrieved 26/11/2012, from European Monitoring Centre for Drugs and Drug Addiction <http://www.emcdda.europa.eu/stats07/tditab02b>
- EMCDDA. (2012a). Table TDI-1. Clients entering treatment and treatment units by country, 2010 or most recent year available. Retrieved 26/11/2012, from European Monitoring Centre for Drugs and Drug Addiction <http://www.emcdda.europa.eu/stats12/tditab1>
- EMCDDA. (2012b). Table TDI-4. Demographic characteristics of clients entering treatment, 2010 or most recent year available. Part (iv) All clients by country and age (%). Retrieved 26/11/2012, from European Monitoring Centre for Drugs and Drug Addiction <http://www.emcdda.europa.eu/stats12/tditab4d>

1 European Monitoring Centre for Drugs and Drug Addiction. (2006). Annual report 2006: selected
2 issues (pp. 57). Luxembourg.

3
4 Forsyth, A. J. M., Khan, F., & McKinlay, B. (2011). Diazepam, alcohol use and violence among male
5 young offenders: 'The devil's mixture'. *Drugs: Education, Prevention, and Policy*, 18(6), 468-
6 476. doi: doi:10.3109/09687637.2011.563762

7
8 Griffin, C. E., 3rd, Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013). Benzodiazepine pharmacology and
9 central nervous system-mediated effects. *Ochsner J*, 13(2), 214-223.

10
11 Hibell, B., Andersson, B., Bjarnason, T., *et al.* (2004). The ESPAD report 2003: alcohol and other drug
12 use among students in 35 European countries.

13
14 Hibell, B., Andersson, B., Bjarnason, T., Kokkevi, A., Morgan, M., & Narusk, A. (1997). The 1995
15 ESPAD Report: Alcohol and Other Drug Use Among Students in 26 European Countries.

16
17 Hibell, B., Andersson, B., Salme, A., *et al.* (2000). The 1999 ESPAD Report: Alcohol and Other Drug
18 Use Among Students in 30 European Countries.

19
20 Hibell, B., Guttormsson, U., Ahlström, S., *et al.* (2012). The 2011 ESPAD Report: Substance Use
21 Among Students in 36 European Countries (pp. 394). Stockholm: The Swedish Council for
22 Information on Alcohol and Other Drugs.

23
24 Irish Medicines Board. (2011). SPC document for VALIUM Retrieved 28/05/2013, from
25 [http://www.imb.ie/images/uploaded/swedocuments/LicenseSPC_PA0050-017-](http://www.imb.ie/images/uploaded/swedocuments/LicenseSPC_PA0050-017-002_13122011221557.pdf)
26 [002_13122011221557.pdf](http://www.imb.ie/images/uploaded/swedocuments/LicenseSPC_PA0050-017-002_13122011221557.pdf)

27
28 Konopka, A., Pełka-Wysiecka, J., Grzywacz, A., & Samochowiec, J. (2013). Psychosocial characteristics
29 of benzodiazepine addicts compared to not addicted benzodiazepine users. *Progress in*
30 *Neuro-Psychopharmacology and Biological Psychiatry*, 40(0), 229-235. doi:
31 <http://dx.doi.org/10.1016/j.pnpbp.2012.09.001>

32
33 Lader, M. (2011). Benzodiazepines revisited—will we ever learn? *Addiction*, 106(12), 2086-2109. doi:
34 [10.1111/j.1360-0443.2011.03563.x](http://dx.doi.org/10.1111/j.1360-0443.2011.03563.x)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Lin, J.-C., Ma, H.-I., & Liu, W.-H. (2013). Severe benzodiazepine withdrawal syndrome followed by anesthesia in elderly patient: A rare case report. *International Journal of Medicine and Medical Sciences*, 5(1), 1-2.
- Mancuso, C. E., Tanzi, M. G., & Gabay, M. (2004). Paradoxical reactions to benzodiazepines: literature review and treatment options. *Pharmacotherapy*, 24(9), 1177-1185.
- Murphy, K., Sahm, L., McCarthy, S., Lambert, S., & Byrne, S. (2013). Substance use in young persons in Ireland, a systematic review. *Addictive Behaviors*, 38(8), 2392-2401. doi: <http://dx.doi.org/10.1016/j.addbeh.2013.03.016>
- National Advisory Committee on Drugs. (2011). *Drug use in Ireland and Northern Ireland, First results from the 2010/11 Drug Prevalence Survey*. Dublin: Retrieved from http://www.nacd.ie/publications/drug_use_ireland.html.
- National Suicide Research Foundation. (2012). National Registry of Deliberate Self Harm Annual Report 2011. Cork: National Suicide Research Foundation,.
- Parsa, A. (2011). Administration of oral midazolam in surgical dentistry. *Oral Surgery*, 4(3), 115-123. doi: 10.1111/j.1752-248X.2011.01125.x
- Sannerud, C. A., Alien, M., Cook, J. M., & Griffiths, R. R. (1991). Behavioral effects of benzodiazepine ligands in non-dependent, diazepam-dependent and diazepam-withdrawn baboons. *European Journal of Pharmacology*, 202(2), 159-169. doi: [http://dx.doi.org/10.1016/0014-2999\(91\)90290-7](http://dx.doi.org/10.1016/0014-2999(91)90290-7)
- Stewart, S. A. (2005). The effects of benzodiazepines on cognition. *J Clin Psychiatry*, 66 Suppl 2, 9-13.
- UNODC. (2007). World Drug Report 2007. Vienna: United Nations Office On Drugs and Crime.
- UNODC. (2012). World Drug Report 2012. Vienna: United Nations Office On Drugs and Crime.
- Verdoux, H., Lagnaoui, R., & Begaud, B. (2005). Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. *Psychol Med*, 35(3), 307-315.

1 World Health Organisation. (1992). *International Statistical Classification of Diseases and Related*
2 *Health Problems-10th Revision.*
3

4 Yeo, J., Jung, J., Ryu, T., Jeon, Y. H., Kim, S., & Baek, W. (2009). Antiemetic efficacy of dexamethasone
5 combined with midazolam after middle ear surgery. *Otolaryngology--Head and Neck*
6 *Surgery, 141(6), 684-688.*
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Breakdown of referrals of service users by source of referral (n=113)

Referral source	% of total referrals (n)
Juvenile Liaison Officer	34.5 (39)
Family	18.6 (21)
Social Worker	16.8 (19)
Probation officer	14.2 (16)
Other	5.3 (6)
Self	3.5 (4)
Youth Centre	3.5 (4)
School	2.7 (3)
Other Treatment Centre	0.9 (1)

Table 2. Service-users that have ever used a substance

Substance	% ever used (n)
Alcohol	98.9 (182)
Cannabis	93.9 (170)
Tobacco	92.7 (153)
Cocaine	54.3 (88)
Benzodiazepines	51.0 (80)
Ecstasy	49.4 (80)
Petrol	34.2 (53)
Amphetamines	28.8 (44)
Head shop	51.4 (37)
Mushrooms	18.5 (28)
Lysergic acid (LSD)	11.8 (18)
Opiates	3.4 (5)
Heroin	50.0 (1)

Table 3. Comparison of service-user characteristics of regular and non-regular benzodiazepine users

Measure	Regular users	Non-regular users	Significance
Mean age \pm S.D. (years)	16.6 \pm 1.02	16.7 \pm 1.20	t=0.585, p=0.561
Gender			
Male (%)	97.5	100.0	p=1.000
Female (%)	2.5	0.0	
Source of referral			
Juvenile Liaison Officer (%)	30.0	28.6	
Probation and Welfare Officer (%)	15.0	21.4	
Social Worker (%)	10.0	21.4	p=0.776
Other (%)	10.0	0.0	
Family (%)	25.0	14.3	
Youth Centre (%)	10.0	7.1	
Self (%)	0.0	7.1	
Median substances ever used	7	7	Z=-1.750, p=0.080
Median substances used in the previous month	3	1	Z=-5.096, p<0.001*
Mean age of first benzodiazepine use	14.8	15.2	t=-1.105, p=0.269

* signifies significance \leq 0.05

Table 4. Comparison of physical and behavioural symptoms experienced by benzodiazepine users

Measure	Regular users	Non-regular	Significance	Total, % (n)
Median behavioural symptoms	12	9	Z=-2.434, p=0.015*	
Behavioural symptoms				
Alcohol or prescription drugs going missing or dwindling in the house	69.4%	55.2%	$\chi^2=0.859$, p=0.354	47.7 (73)
Changing friends and moving away from old friends	79.5%	72.4%	$\chi^2=0.153$, p=0.696	68.9 (111)
Dramatic attention-seeking behaviour	81.3%	50.0%	$\chi^2=5.232$, p=0.022*	65.2 (101)
Extreme apathy	80.6%	60.7%	$\chi^2=1.960$, p=0.161	60.0 (87)
Hyperactivity	83.8%	76.7%	$\chi^2=0.178$, p=0.673	67.7 (109)
Impulsive behaviour	94.7%	83.3%	p=0.227	79.6 (129)
Increased irritability	89.7%	74.2%	$\chi^2=1.947$, p=0.163	78.9 (131)
Increased time spent alone in room/withdrawn behaviour	88.9%	69.0%	$\chi^2=2.837$, p=0.092	63.3 (100)
Loss of interest in sports and hobbies	97.3%	80.0%	p=0.039	76.8 (129)
Low mood	87.2%	73.3%	$\chi^2=1.317$, p=0.251	70.4 (114)
Money/objects missing from home that could be easily converted into cash	66.7%	55.2%	$\chi^2=0.477$, p=0.490	48.4 (74)
Paranoia	94.9%	74.2%	p=0.018*	72.0 (116)
Relationships with peers/siblings/parents affected	94.4%	80.8%	p=0.119	79.7 (122)
Suicidal ideation	35.1%	31.0%	$\chi^2=0.008$, p=0.930	28.0 (44)
Suicide attempts	22.9%	20.7%	$\chi^2=0.000$, p=1.000	15.7 (24)
Temper outbursts	92.3%	80.0%	p=0.163	79.8 (134)
Median physical signs	8	6	Z=-1.969, p=0.049*	

Measure	Regular users	Non-regular	Significance	Total, % (n)
Physical signs				
Blackouts	83.8%	83.3%	p=1.000	71.4 (115)
Bloodshot eyes that appear glassy or vague	85.7%	71.4%	$\chi^2=1.164$, p=0.281	61.3 (93)
Change in appetite	86.1%	67.9%	$\chi^2=2.096$, p=0.148	61.3 (95)
Change in weight	81.6%	60.0%	$\chi^2=2.880$, p=0.090	62.0 (103)
Deterioration in appearance	74.3%	48.3%	$\chi^2=3.535$, p=0.060	54.8 (86)
Excessive sleeping	59.5%	55.6%	$\chi^2=0.003$, p=0.955	49.0 (77)
Insomnia	79.5%	60.7%	$\chi^2=1.979$, p=0.160	59.9 (97)
Loss of fine motor co-ordination e.g. holding a glass	75.0%	60.7%	$\chi^2=0.905$, p=0.341	46.5 (72)
Short-term memory loss	91.7%	93.1%	p=1.000	69.2 (108)
Vomiting or flushed complexion	71.4%	40.7%	$\chi^2=4.702$, p=0.030*	44.1 (67)
White or pale face	86.8%	60.7%	$\chi^2=4.654$, p=0.031*	65.9 (108)

* signifies significance ≤ 0.05

Figure

[Click here to download high resolution image](#)

